CTOs on the Move

Axm Pharma

www.axmpharma.com

 
AXM Pharma, Inc. is a global pharmaceutical company engaged in the production, marketing and distribution of pharmaceutical products in China. The Company produces, markets and distributes medicines in various dosages and forms in areas of medicinal
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.axmpharma.com
  • 7251 W Lake Mead Blvd Ste 300
    Las Vegas, NV USA 89128
  • Phone: 702.562.4155

Executives

Name Title Contact Details

Similar Companies

AEG Vision

AEG Vision supports and empowers eyecare professionals to grow their practices while elevating focus on delivering excellent eyecare.

Maag Prescription

Maag Prescription is a Pocatello, ID-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Secura Bio

Secura Bio™ is a pharmaceutical company committed to giving patients access to innovative therapies. Headquartered in Henderson, Nevada, Secura Bio™ has operations in the U.S. and Offices in San Diego.

PACT Pharma

PACT Pharma is an independent, privately funded company recently launched by Arcus and scientific founders Jim Heath (Caltech), Toni Ribas (UCLA) and David Baltimore (Caltech). PACT`s vision is to be the leader in creating, developing and commercializing cell-based therapies for the cure of cancer. Our mission is to leverage technology developed in the laboratories of Jim Heath and David Baltimore to advance the feasibility, affordability and clinical utilization of personalized neoantigen-specific adoptive cell therapy for cancer. PACT is developing personalized adoptive T cell therapies for the eradication of solid tumors. The identification of neo-epitopes that serve as private mutations for each patient`s cancer creates a unique opportunity to engineer autologous T cells that target and kill tumors expressing these neo-antigens. PACT utilizes technology to identify T cells that recognize the neo-epitope. The unique T-cell receptor (TCR) sequences obtained from these neo-epitope-reactive cells are then engineered into T cells from the patient`s own blood to produce PACT`s therapeutic product: a tsunami of fresh, active T cells that, following infusion into the patient, recognize and attack each patient`s cancer cells.